"Immuno-therapeutic Targeting of AML-Restricted Antigens"

Soheil Meshinchi, MD, PhD
Professor, Translational Science and Therapeutics;
Fred Hutch Cancer Center
Professor of Pediatrics,
University of Washington School of Medicine
Director, COG Hematopoietic Integrated Translational Science Center (HM-ITCS)

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

1. Define the prevalence and underlying etiology of AML across different age groups
2. Define and describe examples of AML-restricted targets
3. Define various modalities of immunotherapeutic targeting of AML-restricted antigens

Speaker Disclosure:
Dr. Meshinchi has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Section # 2099